Verition Fund Management
PTCT icon

Verition Fund Management’s PTC Therapeutics PTCT Stock Holding History

Verition Fund Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Buy
+20,000
New +$1.44M 0.01% 1205

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Verition Fund Management's PTCT Position: Q2 2026 in Review

Verition Fund Management opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 15,000 shares worth $1.22M. The stake represents 0.01% of the portfolio and ranks #1351 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in PTCT as recently as Q4 2025.

Verition Fund Management first reported a position in PTCT in Q1 2018 and has held it in 20 quarters since. The position peaked at $5.64M in Q2 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Verition Fund Management held 15,000 shares of PTC Therapeutics worth $1.22M as of Q2 2026.
  • PTC Therapeutics was a new Verition Fund Management position in Q2 2026.
  • PTC Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1351 holding.
  • Verition Fund Management first reported a position in PTC Therapeutics in Q1 2018 and has held it in 20 quarters since.
  • Verition Fund Management's PTC Therapeutics position peaked at $5.64M in Q2 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.